Latest Orphan drugs Stories
Defitelio®? (defibrotide) Launch Announced During the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 2014 DUBLIN and VILLA GUARDIA, Italy,
Pharmaceutical Executive Brings Additional Expertise in Oncology Drug Development and Commercialization SAN DIEGO, March 25, 2014 /PRNewswire/ --
Incentives for Pathway Compliance, Reduced Hospitalization are Changing Treatment, According to Findings from Decision Resources Group BURLINGTON, Mass., March 4, 2014 /PRNewswire/ -- Decision
SAN DIEGO, Feb. 28, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the U.S.
The global market for histone deacetylase inhibitors (HDIs) was valued at $223.2 million in 2012 and was estimated at $361.8 million for 2013.
-- Study Focused on Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Who are EphA3 Positive -- SOUTH SAN FRANCISCO, Calif., Feb.
Robust Clinical Data on Filanesib Presented at ASH Supporting Announced Registration Program BOULDER, Colo., Feb. 4, 2014 /PRNewswire/ -- Array BioPharma Inc.
Ibrutinib, a small molecule inhibitor of Bruton’s tyrosine kinase, will be investigated in combination with rituximab by the ECOG-ACRIN Cancer Research Group in its latest clinical trial, E1912.
- Growing in low tufty patches.